Merck to seek FDA OK for its COVID pill after trial stopped early
October 4, 2021
“The availability of a well-tolerated, effective oral antiviral will be particularly useful in supplementing vaccination as a means to reduce the proportion of patients needing hospital care.”
Experimental Antibody May Reduce C. diff Recurrence
October 5, 2015
An experimental antibody developed by Merck & Co Inc was shown in pivotal studies to reduce by about 10 percentage points the risk that infection with Clostridium difficile will recur. In the United States, C.